<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33369921</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-3686</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>1</Issue><PubDate><MedlineDate>2021 Jan-Feb 01</MedlineDate></PubDate></JournalIssue><Title>American journal of therapeutics</Title><ISOAbbreviation>Am J Ther</ISOAbbreviation></Journal><ArticleTitle>Severe Hyponatremia Secondary to Riluzole Therapy in Amyotropic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>e164</StartPage><EndPage>e165</EndPage><MedlinePgn>e164-e165</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MJT.0000000000001023</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tambe</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knohl</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gambhir</LastName><ForeName>Harvir Singh</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Tambe</LastName><ForeName>Vikrant</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Ther</MedlineTA><NlmUniqueID>9441347</NlmUniqueID><ISSNLinking>1075-2765</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007010" MajorTopicYN="Y">Hyponatremia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="Y">Neuroprotective Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>28</Day><Hour>14</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33369921</ArticleId><ArticleId IdType="doi">10.1097/MJT.0000000000001023</ArticleId><ArticleId IdType="pii">00045391-202102000-00023</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2002:CD001447.</Citation></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis: ALS/Riluzole Study Group. N Engl J Med. 1994;330:585&#x2013;591.</Citation></Reference><Reference><Citation>Arakawa K, Nishio T, Sunohara N. Two cases of MND/ALS developing the syndrome of inappropriate secretion of antidiuretic hormone. Acta Neurol Scand. 1997;96:262&#x2013;265.</Citation></Reference><Reference><Citation>Yoshida Y, Kato B, Mizushima Y, et al. Syndrome of inappropriate secretion of antidiuretic hormone associated with amyotrophic lateral sclerosis in respiratory failure. Respirology. 1999;4:185&#x2013;187.</Citation></Reference><Reference><Citation>Pillai BP, Unnikrishnan AG, Pavithran PV. Syndrome of inappropriate antidiuretic hormone secretion: revisiting a classical endocrine disorder. Indian J Endocrinol Metab. 2011;15(suppl 3):S208&#x2013;S215.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>